Filtered By:
Source: JAMA
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Intervention for Acute Stroke
In Reply In our recent article, we reviewed major thrombolytic stroke trials and a pooled meta-analysis that confirmed favorable clinical outcome at 3 months if intravenous recombinant tissue plasminogen activator (rtPA) was provided between 3 and 4.5 hours of symptom onset. However, because the majority of patients were contributed by a single European trial, the European Cooperative Acute Stroke Study (ECASS-3), we were careful to state that “… in the 3- to 4.5-hour window, rtPA is recommended for patients with moderately severe symptoms younger than 80 years and without contraindications in some guidelines for stroke management.”
Source: JAMA - August 11, 2015 Category: Journals (General) Source Type: research
Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents The Dual Antiplatelet Therapy Randomized Clinical Trial
ImportanceDespite antirestenotic efficacy of coronary drug-eluting stents (DES) compared with bare metal stents (BMS), the relative risk of stent thrombosis and adverse cardiovascular events is unclear. Although dual antiplatelet therapy (DAPT) beyond 1 year provides ischemic event protection after DES, ischemic event risk is perceived to be less after BMS, and the appropriate duration of DAPT after BMS is unknown.ObjectiveTo compare (1) rates of stent thrombosis and major adverse cardiac and cerebrovascular events (MACCE; composite of death, myocardial infarction, or stroke) after 30 vs 12 months of thienopyridine in pati...
Source: JAMA - March 17, 2015 Category: Journals (General) Source Type: research
